ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SKYE / financials
ACXP (33) ALZN (34) BGMS (38) LGVN (27) ⌘ Pro Terminal →

Skye Bioscience Inc. (SKYE) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.28 -2.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.27

Skye Bioscience Inc. (SKYE) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SKYE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SKYE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Skye Bioscience Inc. (NASDAQ: SKYE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.28 (-2.29% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SKYE ranks #656 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SKYE compare to ACXP and ALZN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SKYE carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and ALZN (Alzamend Neuro Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, SKYE leads on earnings multiple (N/A) while SKYE leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SKYE?
▼

Per SKYE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001516551), Skye Bioscience Inc. generated $162.9M in revenue (+92.6% YoY), -$55.9M in net income, and -$43.1M in free cash flow against $28.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.27 (-0.60%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.9% Base Target
$13 Bull$1 Base$1 Bear
📬 FREE SKYE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SKYE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY SKYE SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$1.53+5.9% Next Q
Q2 (-2Q)
39
Grade E$1.62-10.5% Next Q
Q3 (-1Q)
37
Grade E$1.45-11.7% Next Q
Current
34
Grade E$1.28-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SKYE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SKYE currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.69) and Max Pain ($1.34) forces dealer call-delta covering toward $13.44.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SKYE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SKYE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SKYE Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$162.9MGross Profit $84.7M (52%)Cost of Sales $78.2MOp Profit $0 (0%)OpEx (R&D/SG&A) $84.7MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $97.3M
FY24
Rev $84.5M
FY25
Rev $162.9M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$162.9M52%-35.7%-$55.9M-$43.1M-45%
FY 2024$84.5M52%-35.7%-$26.6M-$26.8M-45%
FY 2023$97.3M52%-35.7%-$37.6M-$14.0M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SKYE)

  • ✓Walkthrough of SKYE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SKYE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.61%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.31H $1.31L $1.28C $1.28VOL 40.6K
RES: $6.64SUP: $1.22SMA50: $1.69SMA200: $4.79
$15.11$11.35$7.60$3.84$0.08RES $6.64SUP $1.22$1.282026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SKYE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SKYE Butterfly Map → + Track SKYE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +92.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SKYE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SKYE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SKYE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SKYE)

Health Care Rank #656 of 1015 ⚔️ ACXP vs SKYE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SKYE vs. ACXP, ALZN, BGMS, LGVN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Skye Bioscience Inc. (SKYE) ranks #656 by composite RQD confidence (34/100, grade E) and #930 by equity capitalization ($5.7M). Within this direct 5-issuer industry benchmark cohort, SKYE leads on earnings valuation at N/A trailing P/E, while SKYE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BGMS currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with SKYE at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SKYE ACTIVE
Skye Bioscience Inc.
E 34/100 — — -35.0% -2.29% $5.7M Benchmark Subject
ACXP
Acurx Pharmaceuticals Inc.
E 33/100 — — -35.0% -2.80% $5.8M /acxp-vs-skye →
ALZN
Alzamend Neuro Inc.
E 34/100 — — -35.0% -0.82% $5.8M /alzn-vs-skye →
BGMS
Bio Green Med Solution Inc.
D- 38/100 — — -35.0% +8.43% $6.0M /bgms-vs-skye →
LGVN
Longeveron Inc. (Class A)
E 27/100 — 67.0% -35.0% -4.57% $5.3M /lgvn-vs-skye →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001516551 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Skye Bioscience Inc. (SKYE) reported GAAP revenue of $162.9M (+92.6% vs. FY2024 revenue of $84.5M , and +67.4% cumulative change since FY2023) , GAAP net income of -$55.9M, operating cash flow of -$43.1M, and free cash flow of -$43.1M (-60.5% YoY). On the balance sheet, SKYE closed FY2025 with $28.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $162.9M -$55.9M -$43.1M -$43.1M $28.3M —
FY2024 (FY) 2024-12-31 $84.5M -$26.6M -$25.2M -$26.8M $72.8M —
FY2023 (FY) 2023-12-31 $97.3M -$37.6M -$14.0M -$14.0M — —

3. SKYE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SKYE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Skye Bioscience Inc. (NASDAQ: SKYE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.28 (-2.29% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SKYE ranks #656 in composite RQD confidence.

How does SKYE compare to ACXP and ALZN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SKYE carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and ALZN (Alzamend Neuro Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, SKYE leads on earnings multiple (N/A) while SKYE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SKYE?

Per SKYE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001516551), Skye Bioscience Inc. generated $162.9M in revenue (+92.6% YoY), -$55.9M in net income, and -$43.1M in free cash flow against $28.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SKYE trading relative to its 50-day, 200-day, and 52-week technical levels?

SKYE last traded at $1.28 (-2.29% on volume of 40,559 shares), positioning the stock -24.26% below its 50-day simple moving average ($1.69) and -73.28% below its 200-day simple moving average ($4.79). Across its 52-week range of $1.25 to $12.80, SKYE sits at the 0.3% percentile with a 14-day RSI of 32.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.12 to $1.44).

Direct Sub-Reports: SKYE RQD Cockpit SKYE 12M Forecast SKYE Earnings & Move SKYE Dividends & DRIP SKYE Insiders & 13F SKYE Whale Options SKYE Profit Sankey SKYE News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

SKYE — Skye Bioscience Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Skye Bioscience Inc. (SKYE) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.28 (-2.29% 1D, market capitalization $5.7M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Skye Bioscience Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry,. The FY 2025 and FY 2024 financials report revenue of — in each year, so the source data shows no reported revenue in the periods covered.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Skye Bioscience Inc. (SKYE) reported $162.9M in annual revenue (up from $84.5M in FY2024, +92.6% YoY) and -$55.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($97.3M revenue, -$37.6M net income) through FY2025, SKYE scaled operating cash flow to -$43.1M and free cash flow to -$43.1M, backed by $28.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.25 – $12.80 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore identifies no upstream suppliers, downstream customers, or sector-correlated counterparties for SKYE. Sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) are the only sector-level context available.

  • Key Question #1: Can SKYE sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $162.9M and free cash flow of -$43.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SKYE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SKYE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Skye Bioscience Inc. (SKYE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SKYE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SKYE Bull vs. Bear Conversation Board — What's Your Call at $1.28?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SKYE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SKYE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $1.61 (+25.8%)
📌 Pinned Debate

The RQD rating's forensic balance sheet pillar still scores 10 / 20, with an Altman Z-Score of 2.5 and a Debt/Equity ratio of 0.5 that

Long SKYE at $1.28 targeting $1.61. The RQD rating's forensic balance sheet pillar still scores 10 / 20, with an Altman Z-Score of 2.5 and a Debt/Equity ratio of 0.5 that show the company is not yet in distress territory on those measures.. Institutional whale score is 3/20 and the risk/reward vs. the $1.25 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

Both sides have a point here — SKYE's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $1.05 (-18.0%)
Spot @ $1.28

Cash fell from $68.4M to $5.9M across the reported fiscal years while the company generated no revenue, and FCF was -$43.1M in FY 2025

Fading this rally in SKYE at $1.28. Cash fell from $68.4M to $5.9M across the reported fiscal years while the company generated no revenue, and FCF was -$43.1M in FY 2025 with ROIC at -35%.. With a beta of 1.0 and the stock sitting at $1.28 (52-wk range $1.25–$12.80), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%